Dan Wang1, Na An2, Yuwei Yang2, Xianggui Yang1, Yingzi Fan1, Jiafu Feng3. 1. Department of Laboratory Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan Province, China. 2. Department of Laboratory Medicine, Mianyang Central Hospital, Mianyang, 621000, Sichuan Province, China. 3. Department of Laboratory Medicine, Mianyang Central Hospital, Mianyang, 621000, Sichuan Province, China. jiafufengacad@foxmail.com.
Abstract
BACKGROUND: Candida tropicalis (C. tropicalis) is an important opportunistic pathogenic Candida species that can cause nosocomial infection. In this study, we analyzed the distribution and drug susceptibility of C. tropicalis and the relationship between ERG11 and UPC2 expression and resistance to azole antifungal agents. METHODS: C. tropicalis was cultured and identified by Sabouraud Agar Medium, CHROM Agar Candida and ATB tests (Bio-Mérieux, France). Total RNA was extracted from the collected strains, and the ERG11 and UPC2 mRNA expression levels were analyzed by quantitative real-time PCR. RESULTS: In total, 2872 clinical isolates of Candida, including 319 strains of C. tropicalis, were analyzed herein; they were mainly obtained from the Departments of Respiratory Medicine and ICU. The strains were predominantly isolated from airway secretion samples, and the detection trend in four years was mainly related to the type of department and specimens. The resistance rates of C. tropicalis to fluconazole, itraconazole and voriconazole had been increasing year by year. The mRNA expression levels of ERG11 and UPC2 in the fluconazole-resistant group were significantly higher than they were in the susceptible group. In addition, there was a significant positive linear correlation between these two genes in the fluconazole-resistant group. CONCLUSIONS: Overexpression of the ERG11 and UPC2 genes in C. tropicalis could increase resistance to azole antifungal drugs. The routine testing for ERG11 and UPC2 in high-risk patients in key departments would provide a theoretical basis for the rational application of azole antifungal drugs.
BACKGROUND: Candida tropicalis (C. tropicalis) is an important opportunistic pathogenic Candida species that can cause nosocomial infection. In this study, we analyzed the distribution and drug susceptibility of C. tropicalis and the relationship between ERG11 and UPC2 expression and resistance to azole antifungal agents. METHODS: C. tropicalis was cultured and identified by Sabouraud Agar Medium, CHROM Agar Candida and ATB tests (Bio-Mérieux, France). Total RNA was extracted from the collected strains, and the ERG11 and UPC2 mRNA expression levels were analyzed by quantitative real-time PCR. RESULTS: In total, 2872 clinical isolates of Candida, including 319 strains of C. tropicalis, were analyzed herein; they were mainly obtained from the Departments of Respiratory Medicine and ICU. The strains were predominantly isolated from airway secretion samples, and the detection trend in four years was mainly related to the type of department and specimens. The resistance rates of C. tropicalis to fluconazole, itraconazole and voriconazole had been increasing year by year. The mRNA expression levels of ERG11 and UPC2 in the fluconazole-resistant group were significantly higher than they were in the susceptible group. In addition, there was a significant positive linear correlation between these two genes in the fluconazole-resistant group. CONCLUSIONS: Overexpression of the ERG11 and UPC2 genes in C. tropicalis could increase resistance to azole antifungal drugs. The routine testing for ERG11 and UPC2 in high-risk patients in key departments would provide a theoretical basis for the rational application of azole antifungal drugs.
Entities:
Keywords:
Candida tropicalis; Drug resistance; ERG11; UPC2
Authors: María J Navarro-Arias; Marco J Hernández-Chávez; Laura C García-Carnero; Diana G Amezcua-Hernández; Nancy E Lozoya-Pérez; Eine Estrada-Mata; Iván Martínez-Duncker; Bernardo Franco; Héctor M Mora-Montes Journal: Infect Drug Resist Date: 2019-04-08 Impact factor: 4.003
Authors: Michael A Pfaller; Daniel J Diekema; John D Turnidge; Mariana Castanheira; Ronald N Jones Journal: Open Forum Infect Dis Date: 2019-03-15 Impact factor: 3.835
Authors: Josephine Kam Tai Dermawan; Subha Ghosh; M Kelly Keating; K V Gopalakrishna; Sanjay Mukhopadhyay Journal: Medicine (Baltimore) Date: 2018-01 Impact factor: 1.889